Biocryst Pharmaceuticals (BCRX) Debt to Equity (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) reported Debt to Equity of -$0.79 for Q1 2026, down 1.62% on a YoY basis from -$0.8 in Q1 2025, and down 143.65% quarter-over-quarter from -$0.32 in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Debt to Equity (2011 - 2026) Analysis & Trends
Biocryst Pharmaceuticals has reported Debt to Equity for 16 years, with the latest figure at -$0.79 in Q1 2026.
- For the quarter ending Q1 2026, Debt to Equity fell 1.62% year-over-year to -$0.79; the trailing twelve-month figure through Mar 2026 stood at -$0.79 (down 1.62% YoY), and the FY2025 full-year result was -$0.32, up 55.8% from the prior year.
- Debt to Equity for Q1 2026 stood at -$0.79, down from -$0.32 in the prior quarter.
- The five-year high for Debt to Equity was -$0.32 in Q4 2025, with the low at -$0.92 in Q3 2022.
- Historically, Debt to Equity has averaged -$0.72 across 5 years, with a median of -$0.73 in 2023.
- Annual changes were most pronounced in 2023 — Debt to Equity retreated 11.28% — and 2025, when it surged 55.8%.
- Biocryst Pharmaceuticals' Debt to Equity stood at -$0.79 in 2022, then climbed by 8.76% to -$0.72 in 2023, then decreased by 1.79% to -$0.73 in 2024, then soared by 55.8% to -$0.32 in 2025, then tumbled by 143.65% to -$0.79 in 2026.
- The last three Debt to Equity figures came in at -$0.79 (Q1 2026), -$0.32 (Q4 2025), and -$0.6 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 2.02 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 2.80 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.01 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.61 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 0.86 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 0.47 |
| 10 | Biocryst Pharmaceuticals | 2.02 Bn | 1.78 Bn | 151.04 Mn | -0.79 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.79 |
| Dec 31, 2025 | -0.32 |
| Sep 30, 2025 | -0.60 |
| Jun 30, 2025 | -0.66 |
| Mar 31, 2025 | -0.77 |
| Dec 31, 2024 | -0.73 |
| Sep 30, 2024 | -0.74 |
| Jun 30, 2024 | -0.72 |
| Mar 31, 2024 | -0.70 |
| Dec 31, 2023 | -0.72 |
| Sep 30, 2023 | -0.73 |
| Jun 30, 2023 | -0.75 |
| Mar 31, 2023 | -0.71 |
| Dec 31, 2022 | -0.79 |
| Sep 30, 2022 | -0.92 |
| Jun 30, 2022 | -0.68 |
| Mar 31, 2022 | -0.85 |
| Dec 31, 2021 | -1.27 |
| Sep 30, 2021 | -0.90 |
| Jun 30, 2021 | -1.20 |